Lexaria Bioscience Corp. is a global innovator in drug delivery platforms designed for the consumer packaged goods and pharmaceutical industries. Its patented DehydraTECH™ drug delivery platform technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier administration methods both orally and topically, lower overall dosing and higher effectiveness for lipophilic (i.e., fat soluble) active substances. DehydraTECH™ increases bio-absorption, enhances potency and tolerability, reduces time of onset, improves cost-effectiveness and masks unwanted tastes for orally administered bioactive molecules with testing demonstrated or underway for cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine, antiviral therapeutics and other molecules. Lexaria has out-licensed DehydraTECH™ to multiple companies in the cannabinoid CPG industry across a wide range of product offerings; and to a world-leading Fortune 100 tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a Health Canada licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and over 60 patents pending worldwide. At Lexaria, Mr. Docherty heads up new product/technology research and development and also serves as a key spokesperson for the company liaising with new and existing shareholders, strategic partners and the media. Mr. Docherty also serves as the company’s “Responsible Person” and principal liaison with Health Canada. Mr. Docherty also serves as an executive management member of Lexaria`s board of directors.

Docherty Management Ltd. is a limited liability corporation that provides strategic and advisory management services to clinical-stage biopharmaceutical and pharmaceutical companies. Clients include companies developing novel drug products for a variety of therapeutic indications, with an emphasis in pain management, neurodegenerative disorders and oncology. Mr. Docherty provides expert guidance to his clients as follows:Capital Markets Development- Development and/or refinement of corporate/investor presentations and related outreach/roadshow materials to attract qualified investorsStrategic Alliances- Identification of and outreach to qualified prospective research collaboration and/or commercial partners Strategic Development / Project Management- Product development plan creation and management;- Third party resource identification and qualification (CMOs, CROs, etc.).

Helix is a publicly listed (TSX, FSE: “HBP”), clinical-stage, biopharmaceutical company focused on the development of biologically-derived, protein therapeutics for the treatment and prevention of cancer. At Helix, Mr. Docherty was a key spokesperson for the Company and provided leadership in the areas listed below. Mr. Docherty also served as a management member of Helix’s board of directors from 2008 to 2012, through which he shared responsibility with the other directors for the overall control and stewardship of the Company. Mr. Docherty’s key accomplishments as Director, President & COO of Helix were as follows:Capital Raising- Facilitated the raising of over $60M in working capital through private placement financings U.S. Capital Markets Expansion- Spearheaded outreach to U.S. investor community- Developed Principal American Liaison relationship upon OTC entry- Regularly liaised with U.S. sell-side biotech analysts- Presented at U.S. sell-side healthcare investor conferencesFinancial Reporting and Investor Relations- Presented to shareholders at the Company’s AGMs- Wrote content for quarterly MD&As, annual reports, AIFs, press releases and Form 20-F filings- Interviewed with biotech reportersStrategic Alliances - Negotiated a license agreement with Helsinn Birex Pharmaceuticals Ltd. (Value: Euro 900,000)- Negotiated an assignment agreement with Helsinn Birex Pharmaceuticals Ltd. (Value: Euro 1M)Strategic Development / Project Management- Developed and spearheaded pharmaceutical development plans for the Company’s lead initiatives - Developed the Company’s strategic business plan- Developed and managed the R&D budget annually- Performed competitive landscape analyses and marketability assessments- Developed and maintained contract relationships with Key Opinion Leaders, CROs, CMOs, regulatory advisors, QPs etc.- Championed presentations to and communications with regulatory authorities domestically and abroad

PharmaDerm was a university spin-off drug delivery company that became a wholly owned subsidiary of Helix BioPharma in 1997 and was later rolled into Helix as a division in 2008. Mr. Docherty became President of PharmaDerm in 2004, where he led a team of 15 researchers in a state-of-the art formulation development, testing and small scale biopharmaceutical manufacturing laboratory. He oversaw all of PharmaDerm’s product development initiatives during this time period and was responsible for annual budget and quarterly financial forecast development and maintenance. He also led an initiative to transition the laboratory to become a GMP (i.e., Good Manufacturing Practice) compliant analytical testing facility. Mr. Docherty was also a member of PharmaDerm’s board of directors.

In this capacity, Mr. Docherty was instrumental in developing and maintaining a key strategic partnership for Helix BioPharma Corp; a license option agreement that was valued at $23.25M in license fees plus an estimated $70M in prospective annual royalties. He also negotiated the sale of Helix’s international commercial rights for Klean Prep™ to a leading, Swiss specialty pharmaceutical company, Helsinn Birex Pharmaceuticals. As well, he developed a fee-for-service, contract formulation development business unit within the Company, continually sought and evaluated new product/technology acquisition opportunities for the Company and took on increasing responsibility for managing the Company’s pharmaceutical development initiatives.

PriceWaterhouseCoopers is one of the world’s largest professional services firms. Its former global pharmaceutical industry practice provided expert consulting services in business strategy, strategic alliance development, organizational strategy, product development, and financial and cost management. At PriceWaterhouseCoopers, Mr. Docherty executed on consulting projects for pharmaceutical clients specializing in product development planning and process optimization. He devised business case solutions and authored company publications for complex problems pertaining to clinical development programs, operations strategy and information management systems.

Nu-Pharm was a former subsidiary of Apotex Inc., specialized in the development of generic and brand name, sterile and non-sterile solution pharmaceuticals. At Nu-Pharm, Mr. Docherty was responsible for designing and implementing the Company’s U.S. regulatory affairs capability. He built this skill set within the regulatory affairs department in the organization, culminating in the development of the Company’s first abbreviated new drug application (ANDA) for submission to the U.S. Food and Drug Administration. He also routinely provided US regulatory affairs guidance and advice to the Company’s R&D, manufacturing and quality departments.

Astra Pharma Inc. (now AstraZeneca) is a world-class innovative pharmaceutical company. At Astra, Mr. Docherty was a member of a team of regulatory affairs professionals who prepared new drug submissions for commercial authorizations in Canada and internationally. He focused primarily on cardiac and respiratory therapies.